I. The Industrial Foundation Behind a Leading Province

Guangdong has long ranked among China's top-tier provinces in pharmaceutical manufacturing. According to the Guangdong Development and Reform Commission's Modern Industrial System Development Report (2023–2024), total revenue from the province's biopharmaceutical and health industry cluster reached RMB 663.8 billion in 2023. Revenue from pharmaceutical manufacturing enterprises above designated size stood at approximately RMB 198.78 billion, placing Guangdong fourth nationally after Jiangsu, Shandong, and Zhejiang.

Behind this ranking lies a structurally diverse manufacturing base: chemical drugs, traditional Chinese medicine (TCM), active pharmaceutical ingredients (APIs), biologics, and medical devices all coexist with distinct leading players. Guangdong's medical device industry has held the national top position for years, accounting for roughly 25% of national output value in 2024, effectively forming a fourth pillar within the broader pharmaceutical manufacturing ecosystem.

It is worth noting that the RMB 663.8 billion figure encompasses health services and medical devices under a broad definition. The narrower pharmaceutical manufacturing segment operates at roughly the RMB 200 billion level. Understanding this distinction is essential for accurately reading Guangdong's true pharmaceutical scale.

II. Cluster Geography: Guangzhou and Shenzhen at the Core

Pharmaceutical manufacturing enterprises concentrate heavily in the Pearl River Delta, with Guangzhou and Shenzhen forming the dual core and other cities playing supporting roles.

In chemical drugs, licensed manufacturers number approximately 170 in Guangzhou, 93 in Shenzhen, 43 in Zhuhai, and 35 in Zhongshan (as of April 2023, based on Guangdong Drug Administration public data). Guangzhou's industrial depth derives from its long pharmaceutical history — Guangyao Group and Guangyao Baiyunshan's main production facilities are both located there. Shenzhen's enterprises skew more toward biotech backgrounds, focusing on high-end formulations and innovative drugs.

In biologics, Guangzhou (50 enterprises) and Shenzhen (48) are nearly matched, reflecting competitive parity in emerging segments.

Zhongshan leverages the National Health Science and Technology Industry Base for a distinctive position in TCM health products. Zhuhai is evolving toward a "new resource allocation center for biopharmaceuticals" through Hengqin policy advantages, with emphasis on standardized modern Chinese medicine and high-end formulations. Foshan and Huizhou fulfill technology transfer and production capacity absorption roles.

This spatial structure reflects the 2021 provincial strategy outlined in Guangdong's Action Plan for Developing the Strategic Pillar Cluster of Biopharmaceuticals and Health (2021–2025): building an ecosystem anchored by Guangzhou and Shenzhen, with Zhuhai, Foshan, Huizhou, Dongguan, and Zhongshan as key supporting nodes.

III. Leading Enterprises: Three Companies Anchoring the Bulk of Output

The dominance of Guangdong's pharmaceutical leaders is clearly visible in listed company disclosures.

Guangyao Baiyunshan (the listed subsidiary of Guangzhou Pharmaceutical Group) reported 2023 revenue of RMB 75.515 billion, up 6.68% year-on-year, with net profit attributable to parent shareholders of RMB 4.056 billion. Guangzhou Pharmaceutical Group overall exceeded RMB 257 billion in revenue (including distribution operations), placing it among China's top three pharmaceutical enterprises. Baiyunshan operates across three coordinated business lines: pharmaceuticals (proprietary Chinese medicine), health consumer goods (including the Wang Laoji brand), and medical distribution.

CR Sanjiu, headquartered in Shenzhen, focuses on consumer health (OTC) and prescription drugs. Its 2023 revenue reached RMB 24.739 billion, up 36.83% year-on-year, with total profit of RMB 3.754 billion. Growth was partly driven by M&A integration, though organic expansion in prescription TCM also remained solid.

Livzon Medical, based in Zhuhai, posted 2023 revenue of RMB 12.43 billion, net profit of RMB 1.95 billion, and R&D expenditure of RMB 1.24 billion — equivalent to 9.9% of revenue. Chemical formulations account for 52.86% of its product mix, APIs for 26.17%, and TCM for 14.04%. Livzon holds a notable competitive position in gonadotropin APIs within the global niche segment, making it a representative Guangdong exporter in the API space.

The combined revenue of these three enterprises far exceeds the aggregate for all Guangdong pharmaceutical manufacturers above designated size, illustrating a structural characteristic of the industry: strong leaders, a thin middle tier, and a large number of small manufacturers with limited individual scale.

IV. Supply Chain: Three Main Lines and Structural Gaps

Guangdong's pharmaceutical manufacturing supply chain can be traced along three main lines.

Chemical drug chain: Upstream covers APIs, where Guangdong has export competitiveness in select niches such as gonadotropins and cardiovascular APIs, but overall API self-sufficiency remains limited. Midstream formulation production is concentrated in Guangzhou and Shenzhen, accounting for roughly half the province's above-scale pharmaceutical enterprises.

TCM chain: Guangdong hosts 177 licensed proprietary Chinese medicine manufacturers — among the highest in the country (source: Qianzhan Industry Research Institute, 2024 TCM Industry Regional Competitive Landscape Analysis). Indigenous Lingnan medicinal materials — Huajuhong (pomelo peel), agarwood, and cardamom — provide distinctive raw material advantages, but cultivation at scale remains a work in progress, leaving upstream supply reliability uncertain.

Biologics and medical devices: This segment has shown the fastest growth in recent years and attracted the most concentrated policy resources. Guangzhou International Bio-Island and Shenzhen Pingshan National Bioindustry Base form the core R&D nodes, but pilot-scale manufacturing and scale-up capabilities remain relatively underdeveloped. Many innovative biologic candidates still rely on contract manufacturing capacity in other provinces.

Structural gaps concentrate at both ends of the chain: upstream (key APIs, high-end cell culture media, specialized research reagents) remains highly import-dependent; downstream (systematic integration of clinical resources, cross-provincial medical insurance negotiation) presents persistent commercialization barriers for new drugs.

V. Pressures and Transformation Challenges

Guangdong's pharmaceutical manufacturing sector faces three converging pressures.

First, sustained volume-based procurement for generic drugs continues to compress margins in the existing business base. Core products of many mid-sized formulators in South China have been included across multiple national procurement rounds, with price reductions typically exceeding 50%. Sales networks built around generic drug promotion are undergoing structural overhaul.

Second, the return timeline for innovative drug R&D is long, and a mature local innovation pipeline has yet to fully emerge. Guangdong has a cohort of innovative drug candidates in clinical stages, but the number that have reached commercialization remains limited. The 38-point action plan issued by the provincial government in October 2024 identified the establishment of three to five nationally leading clinical research platforms by 2027 as a core priority, signaling that innovation translation is now the defining policy objective.

Third, local supply gaps in chemical APIs and certain medicinal herbs remain unresolved. Guangdong has planned dedicated API manufacturing parks, but implementation progress is still unfolding.

VI. Repositioning Priorities Under the Trillion-Yuan Target

In October 2024, the Guangdong provincial government officially issued its Action Plan for High-Quality Development of Guangdong's Biopharmaceutical Industry, targeting a biopharmaceutical and health cluster exceeding RMB 1 trillion and a pharmaceutical manufacturing scale above RMB 500 billion by 2027. These targets imply a compound annual growth rate of roughly 15%, placing incremental growth expectations on emerging segments: high-end medical devices, cell and gene therapy, and AI-assisted drug discovery.

Systematic development of Guangzhou Laboratory, Bio-Island Laboratory, and Shenzhen Bay Laboratory — alongside the cultivation of a local CRO/CMO/CDMO service ecosystem — represents the government's core strategy for bridging the commercialization gap in innovative drug development.

Sales teams supplying raw materials, equipment, packaging, or cold-chain logistics to Guangdong's pharmaceutical manufacturing supply chain can use Tianxia Gongchang to filter pharmaceutical factory directories and decision-maker contact information by region and subcategory across Pearl River Delta cities.

Whether the trillion-yuan target is achievable depends largely on whether innovative drugs can navigate efficiently from laboratory to clinical scale. That remains the defining challenge for Guangdong pharmaceutical manufacturing — beyond any headline revenue figure.

Data Sources

  • Tianxia Gongchang ( — Guangdong pharmaceutical manufacturing factory directory and industry data
  • Guangdong Development and Reform Commission, Modern Industrial System Development Report (2023–2024), February 2025
  • Guangdong Provincial Government Office, Action Plan for High-Quality Development of Guangdong's Biopharmaceutical Industry, October 2024
  • Guangyao Baiyunshan 2023 Annual Report (Shanghai Stock Exchange disclosure)
  • CR Sanjiu 2023 Annual Results Announcement (official website, April 2024)
  • Livzon Medical Group 2023 Annual Report Summary (Shenzhen Stock Exchange disclosure)
  • Qianzhan Industry Research Institute, 2024 TCM Industry Regional Competitive Landscape Analysis
  • OFweek Medical Technology, Pharmaceutical Manufacturing Enterprise Revenue Rankings: Which Province Leads in Biopharmaceuticals?